EUVIMEDEUVIMED entdecken
Crossref

FGFR2 fusion-driven CXCL3 downregulation attenuates neutrophil recruitment in intrahepatic cholangiocarcinoma

Tao Zhu, Jia-Cheng Lu, Yan-Zi Pei, Xiao-Jun Guo, Pei Pu, Xian-Long Meng, Zhi-Qiang Hu, Shu-Yang Hu, Mu Ye, Chen Liang, Dao-Han Zhang, Hai-Ying Zeng und 9 weitere

Cancer Letters · 2026-10 · 657 · 218707

DOI: 10.1016/j.canlet.2026.218707 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026-10. Verfasst von Tao Zhu und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, Shanghai, China; Liver cancer Institute, Zhongsh…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Receptor, Fibroblast Growth Factor, Type 2, Bile Duct Neoplasms, Neutrophil Infiltration. Die Arbeit nennt 39 Literaturangaben. Gefördert von: National Science and Technology Major Project, Shanghai Lingjun Program, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

FGFR2 fusion is a common alteration in malignancies, including intrahepatic cholangiocarcinoma (iCCA). While FGFR2 fusion has oncogenic properties, iCCA patients harboring this alteration demonstrate favorable prognosis, remaining a paradox. Here, we delineated the transcriptomic landscape of FGFR2 fusion-positive iCCA. We observed transcriptional features related to PI3K-AKT signaling in tumor cells and reduced neutrophil infiltration, particularly of the PD-L1+ neutrophil subtype. Mechanistically, FGFR2 fusion was associated with reduced H3K27ac enrichment at the CXCL3 promoter and decreased CXCL3 expression in tumor cells, which may contribute to impaired neutrophil recruitment to tumor tissues. In preclinical models, pharmacological FGFR inhibition increased CXCL3 levels and neutrophil infiltration. Combining neutrophil blockade with clinically available FGFR inhibitors enhanced antitumor activity. In conclusion, this study provides mechanistic insights into the paradox between the oncogenic properties of FGFR2 fusion and favorable clinical outcomes in FGFR2 fusion-positive iCCA, and suggests a potential strategy to optimize FGFR2-targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaReceptor, Fibroblast Growth Factor, Type 2Bile Duct NeoplasmsNeutrophil InfiltrationChemokines, CXCOncogene Proteins, FusionHumansAnimalsCell Line, TumorDown-RegulationMiceGene Expression Regulation, NeoplasticSignal TransductionNeutrophils

Stichwörter der Autor:innen

CXCL3FGFR2 fusionIntrahepatic cholangiocarcinomaNeutrophil

Substanzen

Receptor, Fibroblast Growth Factor, Type 2FGFR2 protein, humanChemokines, CXCOncogene Proteins, Fusion

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, Shanghai, China; Liver cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China; Key Laboratory of Carc…
  • Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address: jclu@fudan.edu.cn.
  • Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, Shanghai, China; Liver cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Liver cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.

Förderung

  • National Science and Technology Major Project
  • Shanghai Lingjun Program
  • China Postdoctoral Science Foundation
  • National Natural Science Foundation of China
  • Ministry of Science and Technology of the People's Republic of China

Zitieren

APA

Zhu, T., Lu, J. C., Pei, Y. Z., Guo, X. J., Pu, P., Meng, X. L., Hu, Z. Q., Hu, S. Y., Ye, M., Liang, C., Zhang, D. H., Zeng, H. Y., Chen, Y., Hou, Y. Y., Ke, A. W., Tang, Z., Zhou, J., Fan, J., Yu, L., …, & Huang, X. Y. (2026). FGFR2 fusion-driven CXCL3 downregulation attenuates neutrophil recruitment in intrahepatic cholangiocarcinoma. Cancer Letters, 657, 218707. https://doi.org/10.1016/j.canlet.2026.218707

Vancouver

Zhu T, Lu JC, Pei YZ, Guo XJ, Pu P, Meng XL, et al. FGFR2 fusion-driven CXCL3 downregulation attenuates neutrophil recruitment in intrahepatic cholangiocarcinoma. Cancer Letters. 2026;657:218707. doi:10.1016/j.canlet.2026.218707

BibTeX
@article{Zhu2026,
  author = {Zhu, Tao and Lu, Jia-Cheng and Pei, Yan-Zi and Guo, Xiao-Jun and Pu, Pei and Meng, Xian-Long and Hu, Zhi-Qiang and Hu, Shu-Yang and Ye, Mu and Liang, Chen and Zhang, Dao-Han and Zeng, Hai-Ying and Chen, Yi and Hou, Ying-Yong and Ke, Ai-Wu and Tang, Zheng and Zhou, Jian and Fan, Jia and Yu, Lei and Shi, Guo-Ming and Huang, Xiao-Yong},
  title = {FGFR2 fusion-driven CXCL3 downregulation attenuates neutrophil recruitment in intrahepatic cholangiocarcinoma},
  journal = {Cancer Letters},
  year = {2026},
  volume = {657},
  pages = {218707},
  doi = {10.1016/j.canlet.2026.218707}
}
Kostenlos starten →